Piper Sandler lowered the firm’s price target on ResMed (RMD) to $248 from $260 and keeps a Neutral rating on the shares. The firm notes the ...

Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder.

Discover ResMed's Q3 2025 earnings highlights, including 8% revenue growth, margin expansion, new product launches, and strategic investments in ...

Refreshing, preservative-free, hypertonic saline solution with natural extracts and essential oils Provides natural relief from nasal congestion caused by sinusitis and allergies Dissolves mucus ...